Company / SG&A per Share
Arrowhead Pharmaceuticals SG&A per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A per Share
$1.00
FY2025
5-year range
$0.50 / $1.00
FY2021-FY2025
Trend
+8.3%
vs FY2024
Sector context
#122 of 210
Health Care
What the data says
At $1.00, Arrowhead Pharmaceuticals's sg&a per share ranks #89 of 210 in the Health Care sector. SG&A per Share has increased for 3 consecutive years, from $0.50 in FY2022 to $1.00 in FY2025.
Based on SEC 10-K filings.
1.00 in FY2025 with a 5-year CAGR of +12.7%.
Increased from $0.76 to $1.00 over the past 2 years.
Health Care sector context is included.
SG&A per Share over time
Growth rates
- 3-Year CAGR
- +25.8%
- 5-Year CAGR
- +12.7%
- 10-Year CAGR
- -
Sector benchmark
#89 of 210 in Health CareTop 42% of 210This company $1.00 Sector average $40.75
▼
-97.6% below sector average
Key checks
Key Insights
- Arrowhead Pharmaceuticals's sg&a per share has grown for 3 consecutive years.
- In FY2025, sg&a per share increased 8.3% year-over-year.
- Ranks #122 out of 210 companies in the Health Care sector.
- Lowest sg&a per share in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score 0.43 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.00 | +8.3% |
| FY2024 | $0.92 | +20.4% |
| FY2023 | $0.76 | +52.5% |
| FY2022 | $0.50 | -36.7% |
| FY2021 | $0.79 | +44.5% |
| FY2020 | $0.55 | +176.8% |
| FY2019 | $0.20 | -37.3% |
| FY2018 | $0.32 | +177.5% |
| FY2017 | $0.11 | -71.3% |
| FY2016 | $0.40 | +520.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026